Cytomx Therapeutics, Inc. annual report, FY2022

CytomX Therapeutics, Inc. — 2022 Form 10-K

Reporting period: Fiscal year ended December 31, 2022; filed March 27, 2023. This is an annual filing, not a standalone fourth-quarter report. The company is a clinical-stage oncology biotech developing conditionally activated biologics through its Probody platform; it has no approved products and has generated no product-sales revenue.

Financial performance and liquidity

Metric	2022	2021
Collaboration revenue	$53.2 million	$37.3 million
Research and development expense	$111.6 million	$114.2 million
General and administrative expense	$42.8 million	$39.2 million
Operating loss	$101.3 million	$116.0 million
Net loss	$99.3 million	$115.9 million
Net loss per share, basic and diluted	$1.51	$1.81
Net cash used in operating activities	$110.8 million	$119.0 million

• Revenue increased 42% year over year, primarily from progress on Astellas and AbbVie programs and new BMS research activity; lower recognized Amgen revenue partly offset the increase. 2022 revenue came from AbbVie ($18.6 million), Astellas ($20.5 million), BMS ($9.1 million) and Amgen ($5.0 million).
• Cash, cash equivalents and short-term investments were $193.7 million at year-end, down from $305.2 million. Current assets were $237.1 million and current liabilities $152.6 million. Management expected existing capital to fund planned operations into 2025, subject to operating results and financing needs.
• Operating cash use was partly offset by $98.3 million of investing cash inflows, mainly maturities of short-term investments. Financing provided $0.6 million in 2022, versus $110.2 million in 2021, which included a $107.7 million net public-offering raise.
• Total liabilities were $346.6 million, including $301.3 million of deferred revenue and $18.1 million of operating lease liabilities. The filing reports no borrowings or debt balance. Stockholders’ deficit was $85.8 million.
• No product gross margin is reported; the business remains pre-commercial and reported an operating loss.

Restatement and changes versus prior periods

• The company restated previously issued 2022 quarterly financial statements after determining that certain collaboration revenue should be recognized using an input method based on actual FTE hours relative to estimated total hours, rather than ratably over the estimated research period. The change affects agreements with BMS, Astellas, and certain AbbVie and Amgen arrangements.
• The filing says the earlier accounting overstated revenue in 2019–2021 and understated deferred revenue at year-end 2020 and 2021. The 2021 annual and quarterly statements were restated in a separate 10-K/A; 2022 quarterly statements are restated here. Investors are instructed to rely on the restated statements, not prior reports or releases.
• Restated 2022 quarterly revenue was $9.0 million in Q1, $12.9 million in Q2 and $11.1 million in Q3. The filing’s quarterly tables show prior reported figures were higher; for example, nine-month revenue was revised from $52.2 million to $33.0 million. Quarterly cash-flow totals were unchanged by the listed restatement adjustments.
• Revenue recognition estimates remain significant: the company reported that changes in estimates increased 2022 revenue by $0.5 million and decreased 2021 revenue by $9.3 million compared with prior-period estimates.

Pipeline, outlook, risks and unusual items

• Pipeline: CX-904, an Amgen-partnered EGFR×CD3 T-cell engager, was in Phase 1 dose escalation. CX-2051 (EpCAM ADC) and CX-801 (masked interferon alpha-2b) were in IND-enabling work, with IND submissions targeted for the second half of 2023. BMS advanced BMS-986288 to Phase 2 in February 2023 and prioritized it as its lead next-generation CTLA-4 program.
• CX-2029: Phase 2 results showed a 21.4% response rate in 14 efficacy-evaluable patients with squamous esophageal cancer and a 10.0% investigator-assessed rate in 30 patients with squamous NSCLC. Across the 92-patient safety population, treatment-related anemia occurred in 82.6% (Grade 3 or higher: 76.1%). On March 21, 2023, AbbVie said it would not pursue further studies and terminated the collaboration; CytomX had a 120-day option to reacquire rights and was evaluating next steps.
• Other program decisions: A 2022 workforce restructuring reduced headcount by approximately 40%, principally in late-stage development. Restructuring charges were approximately $7.7 million and the plan was substantially complete by year-end. Praluzatamab ravtansine was deprioritized pending a partner after mixed Phase 2 results; the TNBC study arms were discontinued. The company had no plans for further pacmilimab development.
• Partnership funding: CytomX entered collaborations with Regeneron and Moderna in late 2022. Regeneron paid $30 million upfront. Moderna’s $35 million upfront payment, including prepaid research funding, was recorded as a receivable and collected in January 2023. Potential milestone totals are contingent, not assured revenue.
• Principal risks: substantial ongoing losses and dependence on additional funding and partner payments; uncertain clinical and regulatory outcomes; safety concerns, especially CX-2029 anemia; reliance on third-party clinical and manufacturing suppliers; competition; and risks that partners discontinue programs. Management’s cash-runway estimate depends on planned spending and anticipated savings.
• Controls and legal matters: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2022 because of a material weakness in ASC 606 collaboration-revenue accounting. Remediation was underway but not yet demonstrated effective. The auditor gave an unqualified opinion on the financial statements but did not audit internal control effectiveness. A patent infringement suit by Vytacera remained pending; the company said it could not reasonably estimate potential loss and recorded no accrual.

Key facts for investors to verify

• Use the restated 2022 quarterly data in this 10-K and the restated 2021 data in the 2021 10-K/A; confirm that comparisons do not rely on superseded filings or releases.
• Track remediation and testing of the material weakness, and whether future collaboration revenue estimates or restatements change.
• Verify CytomX’s decision on the CX-2029 grantback option, funding and clinical plans after AbbVie’s exit, and the clinical significance and manageability of anemia.
• Monitor cash burn, collaboration receipts, restructuring savings and whether management’s stated runway into 2025 remains supportable.
• Check progress and actual timing of CX-904, CX-2051 and CX-801 development milestones, as well as partner decisions and clinical data.
• Follow the Vytacera litigation and any developments in the California tax examination; the filing does not provide a clear estimate of potential exposure for either matter.